Prostrakan Group PLC

Completion of Phase I Clinical Trial of Sancuso[R] in Japanese Volunteers.
Cancer Weekly; 11/17/2009; 1035 words; ...granted on October 27, 2009 to ProStrakan Group plc who developed and own the worldwide...We are very pleased that Prostrakan has obtained the grant of the...for up to 5 consecutive days. Prostrakan launched Sancuso in the U.S...

Swedish Orexo revenue up, loss shrinks 9-mo '09.(Financial report)
Nordic Business Report; 11/10/2009; 600 words; ...application (NDA) for marketing approval of Orexo's cancer pain drug Abstral, filed by UK-based partner ProStrakan Group plc (LSE: PSK), was accepted by the US Food and Drug Administration (FDA) in October. (EUR1 = SEK10.3...

Endo Pharmaceuticals Gives Update on Regulatory Status of FORTESTA™.
Biotech Week; 11/4/2009; 591 words; ...agreement with U.K.-based ProStrakan Group Plc to acquire exclusive U.S...is marketed across Europe by ProStrakan's own, in-house sales forces and is out-licensed by ProStrakan to Bayer Schering Pharma (BSP...

Other News To Note.
BIOWORLD Today; 11/3/2009; 3297 words; ...ownership stake in Bioniche Pharma Group Limited, its sterile injectable...launched in Sweden by its licensee, ProStrakan Group plc, of Galashiels, UK. Tostrex was...diseases. o CeNeS Pharmaceuticals plc, of Cambridge, UK, initiated...

ProStrakan's Agreement With Novartis Could Reach $140M.
BIOWORLD Today; 11/3/2009; 833 words; ...International Correspondent LONDON - ProStrakan Group plc sealed a deal with a headline...bone-related diseases using a ProStrakan target. The Galashiels, Scotland...development and market launch of ProStrakan's five later-stage products...